In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Improvement of lipid profile post cardiac rehabilitation in patients with previous ACS according to the patient's level of risk

Session Poster Session 1

Speaker Alfredo Chauca Tapia

Event : Acute Cardiovascular Care 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes – Prevention
  • Session type : Poster Session

Authors : A Chauca Tapia (Cadiz,ES), R Colman Llamozas (Cadiz,ES), I Noval Morillas (Cadiz,ES), T Bretones Del Pino (Cadiz,ES), L Gutierrez Alonso (Cadiz,ES), R Vazquez Garcia (Cadiz,ES)

A Chauca Tapia1 , R Colman Llamozas1 , I Noval Morillas1 , T Bretones Del Pino1 , L Gutierrez Alonso1 , R Vazquez Garcia1 , 1University Hospital Puerta del Mar, Cardiology - Cadiz - Spain ,


Background: The purpose of this research is to describe the clinical and epidemiological differences  of people admitted to a cardiac rehabilitation program (CRP) after suffering an acute coronary síndrome (ACS) in a tertiary hospital according to their risk level (low, moderate, and high risk) and the effect of cardiac rehabilitation on lipid profile in these three groups.

Methods: Descriptive and analytical study of patients admitted between January 2012 and December 2015 in the CRP of a tertiary hospital. Patients were divided into 3 groups: Low risk (LR) group (n=151), moderate risk (MR) group (n=104) and high risk (HR) group (n=41). Clinical and epidemiological features were analyzed to determine differences between groups. Also, we compared pre and post-CRP lipid profile in the three groups and analyzed the differences of the effect of CRP on lipid profile according to their risk level. 

Results: During the study period, 296 patients were admitted to the CRP, the mean age of each groups were 60.21±9.4yrs(HR), 59.63±7.17yrs(MR) and 57.34±8.54yrs (LR). The only statistically significant differences between groups were the prevalence of DM (p=0.04), the percentage of patients with LVEF=50% (p=0.000) and incomplete revascularization (p=0.010). 
We also compared the pre and postCRP levels of total cholesterol, LDL, HDL and triglycerides. We observed an statistically significant improvement in the four parameters of the lipid profile in the LR group (TC -24.44, p=0.00; LDL -25.63, p=0.00; HDL +4.25, p=0.00; Trig -22.42, p=0.001), in the MR group there was an improvement in three parameters (TC -17.20, p=0.001; LDL -24.01, p=0.00; HDL +6.67, p=0.00),  while in the HR group we only observed improvement in two parameters. (LDL -20.38, p=0.001; HDL +7.67, p= 0.00). 

Conclusion: As we showed in our study, low and moderate risk groups have a greater improvement in lipid profile after CRP compared with high risk patients.

Low risk group Moderate risk group High risk group p value
Men/Women 79.47%/20.53% 76.92%/23.08% 78.05%/21.95% 0.887
Hypertension 45.7% 56.73% 58.54% 0.154
Dyslipidemia 58.94% 68.27% 60.98% 0.311
DM 25.82% 41.34% 48.78% 0.04
Complete CRP 98.67% 93.27% 97.56% 0.067
LVEF <50% 9.27% 28.85% 53.66% 0.000
Incomplete revascularization 15.89% 31.74% 41.46% 0.010
Readmission 9.93% 14.43% 14.63% 0.488

The free consultation period for this content is over.

It is now only available year-round to ACVC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are